SHANGHAI, China & JERSEY CITY, N.J.--BUSINESS WIRE-- ...

Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11 ...

Breast cancer drug Perjeta has been approved by England’s healthcare cost effectiveness watchdog NICE, a breakthrough achieved after Roche offered a substantial price cut. The decision has been ...

The Perjeta-based regimen should be administered for one year as part of a complete regimen for eBC and regardless of the timing of surgery. HER2-positive breast cancer affects almost 100,000 ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to ...

Pertuzumab, trade name Perjeta, can now be used in the treatment of HER2 positive metastatic breast cancer and in aggressive breast cancers which cannot be surgically removed. The drug was ...

Reviewed by David KindnessReviewed by David Kindness Pfizer Inc. (PFE) is a global biopharmaceutical company based in New ...

Today, McCoy takes a handful of pills daily and gets regular infusions of Herceptin and Perjeta, two drugs that target her specific form of cancer, through a permanent chest port. The drugs cost ...

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of ...

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” ...

India - Conduct Of Defendants In A Quia Timet Action. Legal News and Analysis - India - Intellectual Property - Conventus Law ...